In metastatic melanoma patients receiving ACT using TIL, the persistence of infused TIL as well as the enrichment of TIL for certain tumor specificities have been shown to correlate with better clinical response.6 23 We sought to prolong the persistence of CD8+ TIL recognizing the tumor antigen MART-1 by covaccinating with autologous DCs presenting the MART-1 antigen. The gene discussed is CD8A; the disease is metastatic melanoma.